Plain-language guides to the compounds people are talking about. What each one is, how it works, what the science actually shows, and where it stands with regulators.
The gold standard. Fully approved, with the largest weight-loss results ever seen in a drug trial. Beat semaglutide head-to-head by 47% in 2025.
Targets visceral fat specifically, leaving other fat untouched. Strong phase 3 trial data and FDA approved for a defined patient group.
Phase 3 data from May 2026 showed 30% average weight loss at two years — a figure previously only associated with bariatric surgery. Not yet approved.
Supplements reliably raise NAD+ levels that decline with age. Functional benefits for energy and aging are promising and still being confirmed in trials.
The best-evidenced compound here for skin. Controlled trials show measurable collagen and firmness gains. Widely used in premium cosmetics.
Produced in your own mitochondria and linked to metabolic health and exercise capacity. Promising animal data; human trials are the next step.
Unusual for a research peptide: genuine phase 2/3 human trial data across multiple conditions. Results have been mixed, but the evidence base is real.
Extensive animal evidence for accelerated tissue repair. Human trials are lacking, but the mechanism is coherent and the animal data is among the strongest here.
Targets the biological clock at chromosome level. Compelling cell and animal data on telomere extension. Independent human trials are the missing piece.
Each page tells you exactly where a compound stands — approved, in trials, or research-only — and explains the evidence in plain English rather than jargon. Start with About Peptides if the terms are new to you, or go straight to whichever compound you are curious about. Have a question? Get in touch.